221 related articles for article (PubMed ID: 35026476)
21. Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report.
Jin C; He Z; Guo M; Liu S; Wang Y; Qiu J; Li C; Wu D
Anticancer Drugs; 2022 Aug; 33(7):696-700. PubMed ID: 35324529
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer.
Liu W; Huo G; Chen P
Front Public Health; 2024; 12():1213318. PubMed ID: 38435286
[TBL] [Abstract][Full Text] [Related]
23. From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC.
Ou SI; Lee ATM; Nagasaka M
Crit Rev Oncol Hematol; 2023 Jul; 187():104019. PubMed ID: 37187318
[TBL] [Abstract][Full Text] [Related]
24. Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer.
Goto Y; Shukuya T; Murata A; Kikkawa H; Emir B; Wiltshire R; Miura S
Cancer Sci; 2023 Jun; 114(6):2560-2568. PubMed ID: 36866958
[TBL] [Abstract][Full Text] [Related]
25. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M
Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682
[TBL] [Abstract][Full Text] [Related]
26. Rapid regression of neurological symptoms in patients with metastasised ALK+ lung cancer who are treated with lorlatinib: a report of two cases.
Gafer H; de Waard Q; Compter A; van den Heuvel M
BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31345828
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological and clinical properties of lorlatinib in the treatment of
El Darsa H; Abdel-Rahman O; Sangha R
Expert Opin Pharmacother; 2020 Sep; 21(13):1547-1554. PubMed ID: 32511029
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.
Sun S; Pithavala YK; Martini JF; Chen J
J Clin Pharmacol; 2022 Sep; 62(9):1170-1176. PubMed ID: 35373356
[TBL] [Abstract][Full Text] [Related]
29. Clinical Management of Adverse Events Associated with Lorlatinib.
Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT
Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
[TBL] [Abstract][Full Text] [Related]
30. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
Wang L; Sheng Z; Zhang J; Song J; Teng L; Liu L; Li Q; Wang B; Li B
J Chemother; 2022 Apr; 34(2):87-96. PubMed ID: 34139965
[TBL] [Abstract][Full Text] [Related]
31. A pragmatic guide for management of adverse events associated with lorlatinib.
Liu G; Mazieres J; Stratmann J; Ou SI; Mok T; Grizzard M; Goto Y; Felip E; Solomon BJ; Bauer TM
Lung Cancer; 2024 May; 191():107535. PubMed ID: 38554546
[TBL] [Abstract][Full Text] [Related]
32. Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC.
Soo RA; Martini JF; van der Wekken AJ; Teraoka S; Ferrara R; Shaw AT; Shepard D; Calella AM; Polli A; Toffalorio F; Tomasini P; Chiu CH; Kowalski DM; Kim HR; Solomon BJ
J Thorac Oncol; 2023 Nov; 18(11):1568-1580. PubMed ID: 37295609
[TBL] [Abstract][Full Text] [Related]
33. First macrocyclic 3
Basit S; Ashraf Z; Lee K; Latif M
Eur J Med Chem; 2017 Jul; 134():348-356. PubMed ID: 28431340
[TBL] [Abstract][Full Text] [Related]
34. Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients.
Lee PH; Chen KC; Hsu KH; Huang YH; Tseng JS; Yang TY; Chang GC
Anticancer Drugs; 2021 Nov; 32(10):1099-1104. PubMed ID: 34232936
[TBL] [Abstract][Full Text] [Related]
35. Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC.
Ma X; Zhang K; Xu J; Gao H; Yang S; Qin H; Wang H; Gao F; Liu X
Thorac Cancer; 2023 Jul; 14(20):1980-1990. PubMed ID: 37265111
[TBL] [Abstract][Full Text] [Related]
36. Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
De Giglio A; Lamberti G; Facchinetti F; Genova C; Andrini E; Dal Bello MG; Tiseo M; Metro G; Chiari R; Ricciuti B
Clin Lung Cancer; 2020 Sep; 21(5):e478-e487. PubMed ID: 32409267
[TBL] [Abstract][Full Text] [Related]
37. Lorlatinib beyond progression plus platinum/pemetrexed for ALK-positive non-small cell lung cancer patients: report of two cases.
Metro G; Baglivo S; Metelli N; Bonaiti A; Matocci R; Di Girolamo B; Mandarano M; Colafigli C; Bellezza G; Roila F; Ludovini V
J Chemother; 2023 Oct; 35(6):576-582. PubMed ID: 36537289
[TBL] [Abstract][Full Text] [Related]
38. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
39. Lorlatinib as a treatment for ALK-positive lung cancer.
Baba K; Goto Y
Future Oncol; 2022 Aug; 18(24):2745-2766. PubMed ID: 35787143
[TBL] [Abstract][Full Text] [Related]
40. LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion.
Mori S; Izumi H; Araki M; Liu J; Tanaka Y; Kagawa Y; Sagae Y; Ma B; Isaka Y; Sasakura Y; Kumagai S; Sakae Y; Tanaka K; Shibata Y; Udagawa H; Matsumoto S; Yoh K; Okuno Y; Goto K; Kobayashi SS
Commun Biol; 2024 Apr; 7(1):412. PubMed ID: 38575808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]